We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+15.92%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$106M
Cap. Flow
+$85.6M
Cap. Flow %
22.32%
Top 10 Hldgs %
38.06%
Holding
80
New
28
Increased
20
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$13.1M
2
CVS icon
CVS Health
CVS
+$12.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$10.6M
4
IVC
Invacare Corporation
IVC
+$10.3M
5
KIDS icon
OrthoPediatrics
KIDS
+$9.75M

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$39.1M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$13.1M
3
SIBN icon
SI-BONE Inc
SIBN
+$7.62M
4
SNN icon
Smith & Nephew
SNN
+$7.55M
5
CI icon
Cigna
CI
+$5.22M

Sector Composition

Rank Sector Weight
1 Healthcare 85.83%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRIO icon
26
DarioHealth
DRIO
$74.7M
$6.12M 1.6%
+15,894
New +$7.16M
GDRX icon
27
GoodRx Holdings
GDRX
$1.11B
$5.33M 1.39%
136,480
+59,101
+76% +$2.66M
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.14M 1.34%
478,374
-177,367
-27% -$2.19M
CNC icon
29
Centene
CNC
$33.1B
$4.89M 1.28%
76,551
+38,238
+100% +$2.37M
ADAP
30
DELISTED
Adaptimmune Therapeutics
ADAP
$4.86M 1.27%
915,711
-162,466
-15% -$930K
JNJ icon
31
Johnson & Johnson
JNJ
$621B
$4.74M 1.24%
28,854
-27,377
-49% -$4.43M
MREO
32
Mereo BioPharma
MREO
$48.4M
$4.51M 1.18%
+1,339,835
New +$4.74M
INSM icon
33
Insmed
INSM
$21.5B
$4.51M 1.18%
132,422
+8,099
+7% +$310K
RNAC icon
34
Cartesian Therapeutics
RNAC
$245M
$4.13M 1.08%
30,390
-2,629
-8% -$326K
CALT
35
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$3.92M 1.02%
+142,323
New +$4.25M
RGLS
36
DELISTED
Regulus Therapeutics
RGLS
$3.71M 0.97%
+237,656
New +$3.52M
ALBO
37
DELISTED
Albireo Pharma Inc
ALBO
$3.64M 0.95%
103,175
+60,883
+144% +$2.25M
MDVL
38
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$3.22M 0.84%
4,595
+3,326
+262% +$2.39M
APTO
39
DELISTED
Aptose Biosciences, Inc.
APTO
$3.09M 0.81%
1,150
+88
+8% +$174K
SEEL
40
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$3.05M 0.8%
+159
New +$1.86M
ANGO icon
41
AngioDynamics
ANGO
$622M
$3.02M 0.79%
128,865
-56,036
-30% -$1.13M
ZTS icon
42
Zoetis
ZTS
$31.2B
$2.78M 0.73%
17,668
+4,977
+39% +$789K
RCM
43
DELISTED
R1 RCM Inc. Common Stock
RCM
$2.67M 0.7%
+108,246
New +$2.86M
AFMD
44
DELISTED
Affimed
AFMD
$2.62M 0.68%
+33,067
New +$2.15M
DVA icon
45
DaVita
DVA
$12B
$2.58M 0.67%
+23,930
New +$2.66M
ACH
46
Accendra Health
ACH
$227M
$2.41M 0.63%
64,012
-140,372
-69% -$4.39M
IRON icon
47
Disc Medicine
IRON
$3.03B
$2.3M 0.6%
+5,663
New +$2.53M
IMUX icon
48
Immunic
IMUX
$191M
$2.1M 0.55%
13,180
-681
-5% -$116K
MRVI icon
49
Maravai LifeSciences
MRVI
$946M
$2.07M 0.54%
+58,168
New +$1.93M
HAE icon
50
Haemonetics
HAE
$3.8B
$1.68M 0.44%
+15,139
New +$1.87M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Endurant Capital Management held 80 positions worth $384M, up 38% from $277M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Endurant Capital Management deployed $85.6M of net new capital in Q1 2021, opening 28 new positions and adding to 20 existing holdings. Its largest new stake was Sanofi: 272,218 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.1M trimmed.

  • Endurant Capital Management's largest Q1 2021 buy was Sanofi: 272,218 shares worth $13.5M.
  • Endurant Capital Management added most to Iovance Biotherapeutics in Q1 2021, an estimated $10.6M increase.
  • Endurant Capital Management's biggest Q1 2021 reduction was Aclaris Therapeutics, cutting an estimated $13.1M.
  • Endurant Capital Management fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $39.1M.
  • Endurant Capital Management's ten largest holdings make up 38% of its $384M portfolio in Q1 2021.
  • Endurant Capital Management opened 28 new positions and closed 19 in Q1 2021.
  • Endurant Capital Management's portfolio value rose 38% quarter-over-quarter to $384M.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.